# OnCo record tnbc-basal-like-1 (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/tnbc-basal-like-1/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "tnbc-basal-like-1" ;
  schema:name "Basal-like 1 triple-negative breast cancer (BL1)"@en ;
  schema:alternateName "BL1 subtype"@en, "Basal-like 1 TNBC"@en, "Cell-cycle and DNA damage response subtype of TNBC"@en ;
  schema:description "Basal-like 1 is the subtype of triple-negative breast cancer whose cancer cells are busiest dividing and worst at repairing DNA. In the studies that defined it, these tumours were the most likely to disappear completely with chemotherapy before surgery, about four in ten, and their cell lines responded best to platinum drugs."@en ;
  schema:url <https://onco.cc/cancers/tnbc-basal-like-1/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Triple-negative_breast_cancer> ;
  schema:citation <https://doi.org/10.1172/jci45014>, <https://doi.org/10.1371/journal.pone.0157368>, <https://doi.org/10.1158/1078-0432.ccr-13-0799>, <https://doi.org/10.1158/1078-0432.ccr-14-0432>, <https://doi.org/10.1093/annonc/mdy460> ;
  onco:tag "breast", "tnbc", "subtype-page" ;
  onco:related <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-basal-like-2/>, <https://onco.cc/cancers/brca-associated-tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/>, <https://onco.cc/targets/tp53/> ;
  onco:pathways <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/p53-cell-cycle/> ;
  onco:terms <https://onco.cc/terms/basal-like/>, <https://onco.cc/terms/hrd-in-breast-cancer/>, <https://onco.cc/terms/pcr/> ;
  onco:trials <https://onco.cc/trials/geparsixto/>, <https://onco.cc/trials/keynote-522/> ;
  onco:standardOfCare <https://onco.cc/trials/keynote-522/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/technologies/platinum/> .